AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Akero Therapeutics to present at Morgan Stanley Global Healthcare Conference.
ByAinvest
Thursday, Aug 28, 2025 7:03 am ET1min read
Akero Therapeutics, a clinical-stage company, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. The company is developing treatments for serious metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). Their lead product candidate, efruxifermin (EFX), is being evaluated for this condition.
Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The presentation, scheduled for September 8, 2025, at 10:45 a.m. E.T. in New York, will provide investors and industry experts with an update on the company's progress and pipeline.The presentation will highlight Akero's lead product candidate, efruxifermin (EFX), which is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology, SYNCHRONY Outcomes, and SYNCHRONY Real-World. These studies are designed to assess the efficacy and safety of EFX in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, compensated cirrhosis (F4) due to MASH, and MASH or MASLD (metabolic dysfunction associated steatotic liver disease), respectively [1].
The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco and has a strong focus on transforming the lives of patients with serious metabolic diseases [2].
Investors can access the live webcast through the investor relations section of Akero's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the company's website. For further information, contact Christina Tartaglia at Precision AQ (212.362.1200, christina.tartaglia@precisionaq.com) or Peg Rusconi at Deerfield Group (617.910.6217, peg.rusconi@deerfieldgroup.com) [3].
References:
[1] https://www.stocktitan.net/news/AKRO/akero-therapeutics-to-present-at-the-morgan-stanley-23rd-annual-xqhrx6u0xjds.html
[2] https://www.marketscreener.com/news/akero-therapeutics-to-present-at-the-morgan-stanley-23rd-annual-global-healthcare-conference-ce7c50dfde8af722
[3] https://www.stocktitan.net/news/AKRO/akero-therapeutics-to-present-at-the-morgan-stanley-23rd-annual-xqhrx6u0xjds.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet